# Elite Diagnostic Limited

Unaudited Interim Financial Statements

Fourth Quarter ended June 30, 2026

# Contents

| | Page |
|---|---|
| **Directors' report** | 1 |
| **Financial Statements** | |
| Unaudited statement of financial position | 2 |
| Unaudited statement of profit or loss and other comprehensive income | 3 |
| Unaudited statement of changes in equity | 4 |
| Unaudited statement of cash flows | 5 |
| Notes to the interim financial statements | 6 -7 |
| **Additional Information** | |
| Directors and Connected parties Shareholders | 8 |
| Top ten Shareholder | 9 |

# Director's Report

The Board of Directors presents the unaudited financial statements for the fourth quarter ended June 30, 2026.

For the quarter under review, total revenue amounted to $216.5M, representing a 4% decrease compared to $225.0M recorded in the corresponding quarter of 2025. Total revenue for the financial year amounted to $867.3M, an increase of $13.5M over the prior year.

Net Profit for the fourth quarter and the full financial year amounted to $6.0M and $31.5M respectively. The fourth quarter performance was significantly impacted by machine downtime at the Drax Hall location. The Net Profit result for the full financial year was only $0.5M below the prior financial year, notwithstanding the impact of Hurricane Melissa in the second quarter and the extended machine downtime at the Drax Hall location in the fourth quarter.

Administrative expenses for the quarter reflected a reduction of 6**%** when compared to the corresponding period in 2025. This improvement was driven by enhanced procurement practices, bulk purchasing initiatives, and tighter inventory controls, supported by ongoing monitoring and cost discipline.

During the quarter, the Company completed the acquisition of the property intended for the relocation of operations from 1B Holborn Road. The handover and transition process is scheduled for completion in the second quarter of the 2026–2027 financial year.
Total assets amounted to $1.314B compared to **$**1.111B for the corresponding quarter in 2025.
Total liabilities amounted to $739.4M compared to $571.1M for the corresponding quarter in the prior year.

The Board extends its sincere appreciation to our loyal customers, referring physicians and specialist partners for their continued trust and collaboration.

We also thank our shareholders for their ongoing support, and we recognised the dedication and commitment of the entire Elite Diagnostic team, whose efforts continue to sustain the Company's strong presence within the medical diagnostic industry.

---------- ----------

Director - Warren Chung Director - Neil Fong, Dr.

August 03, 2026

# Elite Diagnostic Limited
# Unaudited statement of financial position
June 30, 2026

| | Unaudited June 30, 2026 $000 | Audited June 30, 2025 $000 |
|---|---|---|
| **Assets** | | |
| **Non-current assets** | | |
| Property, plant and equipment | 968,130 | 701,155 |
| Right- of-use-assets | 54,478 | 69,098 |
| Restricted deposit | 20,500 | 20,500 |
| | **1,043,108** | **790,753** |
| **Current assets** | | |
| Deposit on equipment | 21,780 | - |
| Inventory | 15,594 | - |
| Receivables | 91,230 | 85,253 |
| Prepayment | 14,187 | 12,592 |
| Taxation recoverable | 3,813 | - |
| Cash and bank balances | 124,167 | 225,552 |
| | **270,771** | **323,397** |
| **Total assets** | **1,313,879** | **1,114,150** |
| **Equity** | | |
| Share capital | 348,898 | 348,898 |
| Accumulated surplus | 225,612 | 194,107 |
| **Total equity** | **574,510** | **543,005** |
| **Liabilities** | | |
| **Non-current liabilities** | | |
| Lease liabilities | 25,325 | 41,863 |
| Long-term loan | 206,322 | - |
| Unsecured corporate bond | 319,381 | 387,885 |
| Deferred tax liabilities | 6,104 | 6,104 |
| | **557,132** | **435,852** |
| **Current liabilities** | | |
| Current portion of lease liabilities | 35,275 | 30,898 |
| Current portion of long-term loan | 8,192 | - |
| Current portion of unsecured bond | 73,248 | 3,361 |
| Payables and accruals | 56,456 | 91,068 |
| Short term loan | 7,727 | 6,986 |
| Director's loan | 1,339 | 1,339 |
| Taxation payable | - | 1,641 |
| | **182,237** | **135,293** |
| **Total liabilities** | **739,369** | **571,145** |
| **Total equity and liabilities** | **1,313,879** | **1,114,150** |

The notes on the accompanying pages form an integral part of these financial statements.

Approved for issue by the Directors on August 3, 2026 and signed on its behalf by:

**Warren Chung** **Neil Fong**

# Elite Diagnostic Limited
## Unaudited statement of profit or loss and other comprehensive income
Fourth quarter and year ended June 30, 2026

| | Unaudited Three months ended June 30, 2026 $000 | Unaudited Three months ended June 30, 2025 $000 | Unaudited year ended June 30, 2026 $000 | Audited year ended June 30, 2025 $000 |
|---|---|---|---|---|
| **Income** | **216,524** | **225,003** | **867,301** | **853,824** |
| Direct costs | (49,258) | (52,158) | (197,333) | (211,435) |
| **Gross profit** | **167,266** | **172,845** | **669,968** | **642,389** |
| Administrative expenses | (101,920) | (108,759) | (413,494) | (400,901) |
| Depreciation | (45,856) | (43,257) | (179,380) | (170,110) |
| Impairment allowance | | | | 1,933 |
| **Operating profit** | **19,490** | **20,829** | **77,094** | **73,311** |
| Other income | 312 | 117 | 1,276 | 133 |
| Finance costs | (14,577) | (7,775) | (48,314) | (39,144) |
| Gain on foreign exchange | 1,599 | 832 | 3,158 | 2,622 |
| **Profit before tax** | **6,824** | **14,003** | **33,214** | **36,922** |
| Income tax expense | (846) | (159) | (1,709) | (4,898) |
| **Net profit and total comprehensive income for the period** | **5,978** | **13,844** | **31,505** | **32,024** |
| **Basic and diluted earnings per share** | **0.02** | **0.04** | **0.09** | **0.09** |

The notes on the accompanying pages form an integral part of these financial statements.

# Elite Diagnostic Limited
# Unaudited statement of changes in equity
Year ended June 30, 2026

| | Share capital $000 | Accumulated surplus/deficit $000 | Total $000 |
|---|---|---|---|
| **Balance at June 30, 2024 - Audited** | 348,898 | 162,083 | 510,981 |
| Profit for the year ended June 30,2025 being total comprehensive income for the year | - | 32,024 | 32,024 |
| **Balance at June 30, 2025 – Audited** | 348,898 | 194,107 | 543,005 |
| Profit for the year ended June 30, 2026 being total comprehensive income for the period | - | 31,505 | 31,505 |
| **Balance at June 30, 2026 – Unaudited** | **348,898** | **225,612** | **574,510** |

The notes on the accompanying pages form an integral part of these financial statements.

# Elite Diagnostic Limited
# Unaudited statement of cash flows
Year ended June 30, 2026

| | Unaudited June 30, 2026 $000 | Audited June 30, 2025 $000 |
|---|---|---|
| **Cash flows from operating activities:** | | |
| Profit before tax | 33,214 | 36,922 |
| Adjustments for: | | |
| Depreciation | 179,380 | 170,110 |
| Interest expense | 48,314 | 39,144 |
| Interest income | (1,276) | (133) |
| Foreign exchange gain on lease liabilities | (3,150) | (2,433) |
| Adjustment for right of use asset | - | (1,744) |
| | **256,482** | **241,866** |
| Increase in inventories | (15,594) | - |
| (Increase)/decrease in receivables | (5,977) | 57,085 |
| Increase in prepayment | (1,595) | (2,586) |
| (Decrease)/increase in payables and accruals | (34,612) | 3,662 |
| **Cash generated from operations** | **198,704** | **300,027** |
| Income tax paid | (7,163) | (312) |
| Interest paid | (46,931) | (39,144) |
| **Net cash provided by operations** | **144,610** | **260,571** |
| **Cash flow from investing activities** | | |
| Purchase of property, plant and equipment | (415,065) | (92,624) |
| Interest received | 1,276 | 133 |
| Deposit on equipment | (21,780) | - |
| **Net cash used in investing activities** | **(435,569)** | **(92,491)** |
| **Cash flow from financing activities** | | |
| Proceeds from long term loan | 220,000 | - |
| Repayment of long-term loan | (5,486) | (343,653) |
| Proceeds from bond | - | 400,000 |
| Repayment of bond | - | (8,754) |
| Proceeds from short term loan | 10,407 | 9,736 |
| Repayment of short-term loan | (9,666) | (9,525) |
| Repayment of related party loan | - | (2,044) |
| Repayment of lease liabilities | (25,681) | (25,509) |
| **Net cash provided by financing activities** | **189,574** | **20,251** |
| **Net (decrease)/increase in cash and cash equivalents** | **(101,385)** | **188,331** |
| **Cash and cash equivalents at beginning of period/year** | **225,552** | **37,221** |
| **Cash and cash equivalents at end of period/year** | **124,167** | **225,552** |

The notes on the accompanying pages form an integral part of these financial statements.

## 1. General information and nature of operations

Elite Diagnostic Limited was incorporated under the laws of Jamaica on February 12, 2012 and is domiciled in Jamaica. The company commenced operations in August 2013. The company's principal place of business is located at 1b Holborn Road, Kingston 5.

The company provides diagnostic imaging services.

## 2. Statement of compliance

### a Basis of preparation

These financial statements have been prepared in accordance with International Financial Reporting Standards (IFRS) IAS 34, Interim Financial Reporting.

The interim financial report is to be read in conjunction with the audited financial statements for the year ended June 30, 2025. The significant accounting policies adopted are consistent with those of the audited financial statements for the year ended June 30, 2025.

### b Critical judgements and sources of estimation uncertainty

The preparation of these financial statements requires management to make estimates and assumptions that affect the amounts reported in the financial statements. These estimates are based on historical experience and management's best knowledge of current events and actions. Actual results may differ from these estimates and assumptions.

## 3. Share capital

| | Unaudited Year ended June 30, 2026 $ | Audited Year ended June 30, 2025 $ |
|---|---|---|
| Authorised ordinary units of no par value | Unlimited | Unlimited |
| **Issued shares at of no par value** | | |
| Shared capital 353,400,000 ordinary stocks units | **$'000s** | **$'000s** |
| | 348,898 | 348,898 |

## Earnings per shares

| | Unaudited Year ended June 30, 2026 $'000s | Audited Year ended June 30, 2025 $'000s |
|---|---|---|
| Profit attributable to shareholders | 31,505 | 32,024 |
| Weighted average number of shares (000s) | 353,400 | 353,400 |
| Earnings per shares | 0.09 | 0.09 |

## Earnings per shares

| | Unaudited Three months ended June 30, 2026 $'000s | Unaudited Three months ended June 30, 2025 $'000s |
|---|---|---|
| Profit attributable to shareholders | 5,978 | 13,844 |
| Weighted average number of shares (000s) | 353,400 | 353,400 |
| Earnings per shares | 0.02 | 0.04 |

# Elite Diagnostic Limited
## List of Directors, Connected Parties and Senior Managers Shareholdings
As at June 30, 2026

### Directors and connected parties

### Directors

| Name | Position | Shares Held | Percentages % |
|---|---|---|---|
| Steven Gooden | Chairman | 35,289,628 | 9.9857 |
| Warren Chung | Director | 778,355 | 0.2203 |
| Neil Fong | Director | 140,000 | 0.0396 |
| Mark Kerr-Jarrett | Director | - | - |
| Quentin Hugh Sam | Director | 824,573 | 0.2333 |
| Simone Bowie Jones | Director | - | - |
| Stephen Ricketts | Director | - | - |
| | | **37,032,556** | **10.4789** |
| **Combined Directors Holdings** | | | |

| Connected Parties | Connected to | | |
|---|---|---|---|
| Excel Investments Inc | Warren Chung and Neil Fong | 86,674,897 | 24.5260 |
| Barnett Limited | Mark Kerr-Jarrett | 15,515,994 | 4.3905 |
| NCB Capital Markets Limited | Stephen Ricketts | 66,028,392 | 18.6838 |
| | | **168,219,283** | **47.6003** |
| **Combined Holdings** | | **205,251,839** | **58.0792** |

### Senior Managers' Shareholdings

| Name | Position | Shares Held | Percentages % |
|---|---|---|---|
| Neil Fong | Chief Operating Officer | 140,000 | 0.0396 |
| Marjorie Miller | General Manager | - | - |
| | | **140,000** | **0.0396** |
| **Combined Senior Managers Holdings** | | | |

| Connected Parties | Connected to | | |
|---|---|---|---|
| Excel Investments Inc | Neil Fong | 86,674,897 | 24.5260 |
| | | **86,674,897** | **24.5260** |
| **Combined Connected Parties Holdings** | | 86,814,897 | 24.5656 |
| **Total issued capital** | | **353,400,000** | |

# Elite Diagnostic Limited
## List of Top 10 Shareholders
As at June 30, 2026

**Top 10 Shareholders**

| Names | Share Held | Percentages % |
|---|---|---|
| 1. Excel Investments Inc (Connected to Warren Chung and Neil Fong) | 86,674,897 | 24.5260 |
| 2. NCB Capital Markets Limited (Connected to Stephen Ricketts) | 66,028,392 | 18.6838 |
| 3. Steven Gooden | 35,289,628 | 9.9857 |
| 4. JCSD Trustee Services Limited - Sigma Optima | 31,438,024 | 8.8959 |
| 5. Barnett Limited (Connected to Mark Kerr-Jarrett) | 15,515,994 | 4.3905 |
| 6. Damian Chin-You | 14,513,589 | 4.1068 |
| 7. West Indies Radiology Outsourcing Ltd. | 8,000,000 | 2.2637 |
| 8. Everton J. Smith | 6,652,093 | 1.8823 |
| 9. Kenroy Lue | 5,053,963 | 1.4301 |
| 10. Pooled Equity Fund | 4,105,594 | 1.1617 |
| **Total units owned by top 10 Shareholders** | **273,272,174** | **77.3265** |
| **Total Issued Capital** | **353,400,000** | |